Compound class:
Synthetic organic
Comment: Compound 41 is a structurally novel, potent, selective and orally bioavailable PI3Kδ inhibitor [1]. Results from this inhibitor optimisation study suggest that off-target inhibition of Vps34 is associated with in vivo toxicity in a rat PK model.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
Compared to other inhibitors in the study (e.g. 19), 41 has lower toxicity and an acceptable pharmacokinetic profile for oral dosing, along with good primary activity and an enhanced selectivity profile [1]. Using the lipid kinobead assay 41 was determined to bind >600-fold more potently to PI3Kδ than to the other class I PI3Ks, and >200-fold more potently to PI3Kδ than to Vps34 (a class III PI3K enzyme). |
Selectivity at enzymes | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|